JP6347949B2 - 改良型細胞培養培地 - Google Patents

改良型細胞培養培地 Download PDF

Info

Publication number
JP6347949B2
JP6347949B2 JP2013506612A JP2013506612A JP6347949B2 JP 6347949 B2 JP6347949 B2 JP 6347949B2 JP 2013506612 A JP2013506612 A JP 2013506612A JP 2013506612 A JP2013506612 A JP 2013506612A JP 6347949 B2 JP6347949 B2 JP 6347949B2
Authority
JP
Japan
Prior art keywords
cells
medium
cell culture
culture
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013506612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013524825A5 (OSRAM
JP2013524825A (ja
Inventor
ライスト，クリスチャン
マイズナー，ペトラ
シュミト，ヨルグ
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44074260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6347949(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2013524825A publication Critical patent/JP2013524825A/ja
Publication of JP2013524825A5 publication Critical patent/JP2013524825A5/ja
Application granted granted Critical
Publication of JP6347949B2 publication Critical patent/JP6347949B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/005—Protein-free medium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2013506612A 2010-04-26 2011-04-25 改良型細胞培養培地 Active JP6347949B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32783610P 2010-04-26 2010-04-26
US61/327,836 2010-04-26
PCT/EP2011/056508 WO2011134920A1 (en) 2010-04-26 2011-04-25 Improved cell culture medium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016152747A Division JP6603628B2 (ja) 2010-04-26 2016-08-03 改良型細胞培養培地

Publications (3)

Publication Number Publication Date
JP2013524825A JP2013524825A (ja) 2013-06-20
JP2013524825A5 JP2013524825A5 (OSRAM) 2014-06-05
JP6347949B2 true JP6347949B2 (ja) 2018-06-27

Family

ID=44074260

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013506612A Active JP6347949B2 (ja) 2010-04-26 2011-04-25 改良型細胞培養培地
JP2016152747A Active JP6603628B2 (ja) 2010-04-26 2016-08-03 改良型細胞培養培地
JP2019142124A Active JP7034991B2 (ja) 2010-04-26 2019-08-01 改良型細胞培養培地

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016152747A Active JP6603628B2 (ja) 2010-04-26 2016-08-03 改良型細胞培養培地
JP2019142124A Active JP7034991B2 (ja) 2010-04-26 2019-08-01 改良型細胞培養培地

Country Status (17)

Country Link
US (2) USRE48864E1 (OSRAM)
EP (1) EP2563904B1 (OSRAM)
JP (3) JP6347949B2 (OSRAM)
KR (1) KR101828623B1 (OSRAM)
CN (1) CN102858952B (OSRAM)
AU (1) AU2011246503B2 (OSRAM)
BR (1) BR112012027282B1 (OSRAM)
CA (1) CA2797356C (OSRAM)
DK (1) DK2563904T3 (OSRAM)
ES (1) ES2533074T3 (OSRAM)
IL (1) IL222452B (OSRAM)
MX (1) MX2012012526A (OSRAM)
PL (1) PL2563904T3 (OSRAM)
PT (1) PT2563904E (OSRAM)
RU (1) RU2644651C2 (OSRAM)
SG (1) SG185038A1 (OSRAM)
WO (1) WO2011134920A1 (OSRAM)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
EP2500413A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
JP5808249B2 (ja) 2008-10-20 2015-11-10 アッヴィ・インコーポレイテッド プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製
SG10201702951RA (en) 2008-10-20 2017-06-29 Abbvie Inc Viral inactivation during purification of antibodies
PL2563904T3 (pl) * 2010-04-26 2015-06-30 Novartis Ag Udoskonalona pożywka do hodowli komórkowej
CA2797140C (en) 2010-04-26 2018-01-23 Novartis Ag Improved cell culture medium
JP5824527B2 (ja) * 2010-12-07 2015-11-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 供給物混合装置およびその使用
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
KR20140079491A (ko) 2011-10-18 2014-06-26 코히러스 바이오사이언시즈, 인코포레이티드 당과 폴리올과의 배합물로 안정화된 에타너셉트 제형
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
PE20150762A1 (es) 2012-07-09 2015-06-20 Coherus Biosciences Inc Formulaciones de etanercept que muestran una marcada reduccion de la cantidad de particulas subvisibles
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
SG11201501460RA (en) 2012-09-11 2015-04-29 Coherus Biosciences Inc Correctly folded etanercept in high purity and excellent yield
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
KR20150129033A (ko) 2013-03-14 2015-11-18 애브비 인코포레이티드 저 산성 종 조성물 및 이의 제조 및 사용 방법
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
CN105473614B (zh) 2013-08-20 2019-11-01 斯洛文尼亚莱柯制药股份有限公司 用于控制多肽的α-酰胺化和/或C-末端氨基酸分裂的细胞培养基和方法
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
PL3055409T3 (pl) * 2013-10-11 2018-10-31 Regeneron Pharmaceuticals, Inc. Metabolicznie zoptymalizowana hodowla komórkowa
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EA037238B1 (ru) * 2014-01-30 2021-02-25 Кохерус Байосайенсис, Инк. Перфузионная среда
PT3536776T (pt) 2014-04-29 2024-01-12 Novartis Ag Novas células de vertebrados e métodos para expressão de forma recombinante de um polipéptido de interesse
ES2733298T3 (es) 2014-07-18 2019-11-28 Sandoz Ag Cuantificación de TNFR2:Fc plegado erróneamente
US10822584B2 (en) * 2015-12-17 2020-11-03 Life Technologies Corporation Pellets used in cell culture and methods of making thereof
ES2992543T3 (es) * 2016-04-05 2024-12-13 Pfizer Proceso de cultivo celular
JP6943972B2 (ja) * 2017-03-31 2021-10-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 灌流培地
US20200377918A1 (en) * 2017-03-31 2020-12-03 Boehringer Ingelheim International Gmbh Perfusion medium
EP3959305A1 (en) 2019-04-26 2022-03-02 Allogene Therapeutics, Inc. Methods of manufacturing allogeneic car t cells
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
WO2021090888A1 (ja) * 2019-11-05 2021-05-14 味の素株式会社 タンパク質の製造方法
JP2023521236A (ja) * 2020-04-15 2023-05-23 ジェネンテック， インコーポレイテッド 接種前の培養培地の処理方法
WO2022036275A2 (en) * 2020-08-14 2022-02-17 Bristol-Myers Squibb Company Manufacturing process for protein
UY39484A (es) 2020-11-02 2022-06-30 Novartis Ag Inhibidores de interleucina-17
CN114606200B (zh) * 2022-02-10 2025-07-18 上海迈邦生物科技有限公司 Sp2/0细胞培养基及生产重组犬细小病毒单克隆抗体的方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
DE3871206D1 (de) 1987-03-24 1992-06-25 Grace W R & Co Basisnaehrmedium fuer eine zellkultur.
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US4929706A (en) 1988-11-02 1990-05-29 W. R. Grace & Co.-Conn. Cell growth enhancers and/or antibody production stimulators comprising chemically modified hydrophilic polyurea-urethane prepolymers and polymers
CA2001550A1 (en) 1989-03-03 1990-09-03 Aaron H. Heifetz Very low protein nutrient medium for cell culture
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
JPH0789908B2 (ja) 1991-02-28 1995-10-04 倉敷紡績株式会社 動物細胞培養用無血清培地
GB9118664D0 (en) 1991-08-30 1991-10-16 Celltech Ltd Cell culture
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5830761A (en) 1995-06-07 1998-11-03 Genetics Institute, Inc. Medium and methods for culturing mammalian cho cells
EP2218775B1 (en) 1996-08-30 2015-01-28 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
EP1757700A3 (en) 1999-04-26 2009-03-11 Genentech, Inc. Cell culture process for glycoproteins
AU4980200A (en) 1999-05-27 2000-12-18 Pharmacia & Upjohn Company Methods and compositions for measuring ion channel conductance
AT409379B (de) * 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
AU780653B2 (en) 1999-12-28 2005-04-07 Isotis N.V. Cell culture medium containing growth factors and L-glutamine
DE60230858D1 (de) 2001-02-15 2009-03-05 Centocor Inc Chemisch definiertes medium für kultivierte säugerzellen
WO2002101019A2 (en) 2001-06-13 2002-12-19 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
CA2492267C (en) 2002-07-15 2013-09-10 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
CA2511520A1 (en) 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
GB0304799D0 (en) 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
DE10338536A1 (de) 2003-08-19 2005-04-07 Bircher Reglomat Ag Verfahren zum Betreiben eines Radarsensors
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
EP1937798A4 (en) 2005-04-15 2009-05-13 Univ Columbia CHEMICALLY DEFINED CULTURAL MEDIA FOR THE EXPANSION AND DIFFERENTIATION OF EPIDERMIC CELLS AND USES THEREOF FOR THE IN VITRO FARMING OF HAIRFOLLICLES
US20070231895A1 (en) 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
CN104152395B (zh) * 2006-11-08 2020-03-10 惠氏公司 合理设计的细胞培养基
PL2563904T3 (pl) 2010-04-26 2015-06-30 Novartis Ag Udoskonalona pożywka do hodowli komórkowej

Also Published As

Publication number Publication date
RU2018101201A (ru) 2019-02-21
WO2011134920A1 (en) 2011-11-03
RU2644651C2 (ru) 2018-02-13
BR112012027282B1 (pt) 2020-09-29
AU2011246503A1 (en) 2012-11-22
USRE48864E1 (en) 2021-12-28
MX2012012526A (es) 2012-11-23
KR101828623B1 (ko) 2018-02-12
US9428727B2 (en) 2016-08-30
US20130122543A1 (en) 2013-05-16
JP2019216728A (ja) 2019-12-26
IL222452B (en) 2019-03-31
JP2017012180A (ja) 2017-01-19
IL222452A0 (en) 2012-12-31
EP2563904A1 (en) 2013-03-06
JP6603628B2 (ja) 2019-11-06
KR20130058699A (ko) 2013-06-04
RU2018101201A3 (OSRAM) 2021-05-27
JP7034991B2 (ja) 2022-03-14
CN102858952B (zh) 2015-10-14
BR112012027282A2 (pt) 2015-09-22
CA2797356C (en) 2020-12-29
SG185038A1 (en) 2012-11-29
JP2013524825A (ja) 2013-06-20
PT2563904E (pt) 2015-05-12
RU2012150346A (ru) 2014-06-10
ES2533074T3 (es) 2015-04-07
CN102858952A (zh) 2013-01-02
DK2563904T3 (en) 2015-04-07
CA2797356A1 (en) 2011-11-03
PL2563904T3 (pl) 2015-06-30
AU2011246503B2 (en) 2013-09-26
EP2563904B1 (en) 2015-01-21

Similar Documents

Publication Publication Date Title
JP6603628B2 (ja) 改良型細胞培養培地
KR101828624B1 (ko) 개선된 세포 배양 방법
KR101362805B1 (ko) 개선된 세포 배양 배지
KR101848945B1 (ko) 개선된 세포 배양 배지
RU2798069C2 (ru) Улучшенная среда для культивирования клеток

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160803

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160921

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20161118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180530

R150 Certificate of patent or registration of utility model

Ref document number: 6347949

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250